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Abstract
Adjuvant endocrine therapy is a pivotal component of treatment for
premenopausal women with early-stage hormone receptor-positive
breast cancer. Currently, the standard endocrine therapy for
premenopausal women is tamoxifen; a role for ovarian suppression
or ablation has also been identified. Uncertainty remains about the
optimal use of endocrine therapy in this setting. The role of ovarian
suppression with tamoxifen or aromatase inhibitor, the optimal
duration of adjuvant endocrine therapy and the utility of biomarkers
and pharmacogenetic studies to select therapy are questions
worthy of further investigation.
Endocrine therapy interrupts the estrogen-estrogen receptor
alpha (ER) signaling pathway by either interfering with ER-
ligand interaction through the use of selective ER modulators
(SERMs) like tamoxifen or decreasing production of the
ligand, estrogen, via ovarian ablation or suppression (OA/OS)
or aromatase inhibition. These interventions represent some
of the first targeted therapies to treat any type of cancer. They
exemplify the power of understanding the role of a biological
pathway by careful target identification and selective
targeting of that pathway. Unfortunately for premenopausal
women with endocrine-responsive breast cancer, we ignored
cancer biology and treated these women with chemotherapy
alone for a number of years. Only more recently have we
rightly reinstated endocrine therapy as the most important
part of management of premenopausal women with early-
stage hormone receptor (HR)-positive breast cancer.
In 1896, Sir George Beatson successfully palliated meta-
static breast cancer in young women with bilateral oophorec-
tomy and established the role of endocrine therapy in the
form of OA in managing women with breast cancer [1]. Fifty
years later, investigators from the Christie Hospital in England
conducted the first randomized controlled trial of ovarian
irradiation in breast cancer patients, which, along with five
succeeding randomized clinical trials, further confirmed a role
for OA in managing premenopausal women with operable
breast cancer [2]. The 1970s brought the belief that
endocrine therapy was less effective in premenopausal
women as initial trials in unselected patients showed that
chemotherapy, rather than endocrine therapy, improved the
overall survival of these women. It was not until the 1990s
when serial reports of the early Breast Cancer Trialists’
Collaborative Group (EBCTCG) meta-analysis reaffirmed the
efficacy of OA/OS in women younger than 50 years of age by
demonstrating that OA/OS reduced the incidence of breast
cancer recurrence and mortality by 30% [3]. Meanwhile,
researchers also postulated that the benefit of adjuvant
chemotherapy might be partially derived from chemotherapy-
induced OS, a common consequence of chemotherapy in
premenopausal women. These findings stimulated a series of
randomized controlled trials evaluating the efficacy of OA/OS
versus chemotherapy or in addition to chemotherapy.
Unfortunately, none of those clinical trials incorporated
tamoxifen because of another false belief that tamoxifen was
ineffective in premenopausal women. Indeed, it was not until
1995 that the EBCTCG overview unequivocally rejected this
misconception about tamoxifen by demonstrating its efficacy
in lowering the breast cancer recurrence rate and mortality in
premenopausal women with HR-positive breast cancer.
Currently, tamoxifen is the standard adjuvant endocrine
therapy in premenopausal women, and monotherapy with OS
is considered a reasonable alternative if pregnancy is
planned. Some practitioners also accept a role for OS plus
tamoxifen [4].
The benefits of tamoxifen in premenopausal women with HR-
positive breast cancer have stood the test of time. The 2000
EBCTCG meta-analysis demonstrated that, in women with
HR-positive breast cancer, five years of adjuvant tamoxifen
halved the annual recurrence rate and reduced breast cancer
related mortality by 31%, regardless of age, nodal status or
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use of chemotherapy [3]. Five years of tamoxifen was noted
to be more effective than one to two years of tamoxifen [3].
Small clinical trials comparing five years to ten years of
tamoxifen treatment failed to demonstrate superiority of
therapy of longer duration, leading to the current practice of
five years of tamoxifen [3]. Two ongoing large randomized
clinical trials, Adjuvant Tamoxifen Treatment-Offer More
(aTTom) and Adjuvant Tamoxifen-Longer against Shorter
(ATLAS), should add to our understanding about the optimal
duration of adjuvant tamoxifen use in premenopausal women.
OA/OS can be achieved by surgery, radiation, chemotherapy,
or gonadotrophin hormone-releasing hormone (GnRH)
agonists such as goserelin, leuprorelin and triptorelin [5]. If
ovarian targeted therapy is to be used, the 2007 St Gallen
panel recommended GnRH agonist as a first line agent for
OS, and accepted oophorectomy as a reasonable alternative;
radiation induced OA was universally rejected [4].
The efficacy of OS compared to chemotherapy or in addition
to chemotherapy has been investigated in numerous clinical
trials [6]. A recently published meta-analysis collected data
from 16 randomized clinical trials involving 9,022 premeno-
pausal women with early-stage HR-positive breast cancer.
Use of GnRH agonist alone showed a non-significant
reduction in recurrence rate and death after breast cancer
but this analysis included only 338 patients and lacked
statistical power. GnRH agonists showed similar efficacy to
chemotherapy (largely CMF-like) in trials that enrolled 3,184
women. The meta-analysis also failed to show significant
superiority of GnRH agonist plus tamoxifen over tamoxifen or
chemotherapy. It did, however, show an additional benefit of
GnRH agonist when used with chemotherapy with or without
tamoxifen in both recurrence rate (hazard ratio 0.88, 95%
confidence interval 0.77 to 0.99, p = 0.04) and disease-free
survival (hazard ratio 0.85, 95% confidence interval 0.73 to
0.99, p = 0.04). This additional benefit was noted in women
younger than 40 years of age, in whom chemotherapy-
induced amenorrhea is less common, and was not observed
in women 40 years or older who are likely to become
postmenopausal as a consequence of chemotherapy. As few
patients in these trials were given tamoxifen in both arms, it is
not possible to evaluate whether GnRH adds to the benefit
obtained from tamoxifen. The meta-analysis concluded that
GnRH agonists were effective agents in treating
premenopausal women with HR-positive early breast cancer
[7]. Even though this analysis is the most comprehensive
examination of the use of GnRH agonists in early breast
cancer, it is limited by insufficient statistical power for some
of the questions posed. Also, some might argue that the
chemotherapy studied is not contemporary as only a minority
of trials used anthracycline-based chemotherapy and none
employed a taxane. Most importantly, none of the trials used
tamoxifen in an optimal fashion; in particular, no study
compared GnRH agonist plus tamoxifen with chemotherapy
plus tamoxifen.
The role of OA by surgery has also come under scrutiny again
with the advent of testing for BRCA1 and BRCA2 mutation in
women in hereditary breast cancer families. It has been
recognized that prophylactic oophorectomy can reduce risk
of developing both breast and ovarian cancer in such women
[8]. Mutation carriers are often identified at the time of breast
cancer diagnosis. By extrapolation from other data sets, it
seems likely that prophylactic oophorectomy that may be
pursued by these women might be a useful adjuvant therapy
for HR-positive breast cancer.
Failure to recognize the importance of endocrine therapy,
especially tamoxifen, in the treatment of premenopausal
women with breast cancer led to a lag in identifying the
optimal use of endocrine therapy. Thus, several questions
remain to be answered, and the role of combination endo-
crine therapy is one of them. The strategy of GnRH agonist
plus tamoxifen has not been shown to be superior to either
approach alone in early breast cancer. Also, although mono-
therapy with aromatase inhibitors alone is not indicated in
premenopausal women, the combination therapy of OS and
aromatase inhibitors is a rational and intriguing consideration.
Several of these unanswered questions will be addressed in
ongoing trials. The Suppression of Ovarian Function Trial
(SOFT) compares the efficacy of tamoxifen versus OS plus
tamoxifen versus OS plus exemestane for five years in
premenopausal women with HR-positive breast cancer; this
trial includes women who have received adjuvant chemo-
therapy and remain premenopausal thereafter. Successful
completion of this trial is vital as it will identify the optimal
endocrine therapy regimen for premenopausal women. Two
trials are further examining the role of combined endocrine
therapy. Both the Tamoxifen and Exemestane Trial (TEXT)
and Austrian Breast Cancer Trial 12 are randomizing women
to OS plus tamoxifen or to OS plus aromatase inhibitor.
Unfortunately, both the Premenopausal Endocrine Respon-
sive Chemotherapy Trial (PERCHE) and Premenopausal
Optimal Management IS Endocrine therapy (PROMISE) trials
were closed early due to poor accrual. Hence, the most
important question of whether premenopausal women with
early-stage HR-positive breast cancer receiving combined
endocrine therapy would benefit from chemotherapy will likely
never be answered in a prospective fashion.
In addition, the optimal duration of endocrine therapy for pre-
menopausal women to balance the potential benefits and
side effects associated with the treatment needs to be deter-
mined. Endocrine therapy significantly affects reproductive
options in premenopausal women as women are counseled
not to become pregnant during the several years of adjuvant
endocrine therapy. Young women may also experience
menopausal symptoms, such as hot flushes, vaginal dryness
and sexual dysfunction, with any of these endocrine
therapies. The long term side effects of endocrine therapy on
bone health, cognitive function and cardiovascular health also
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Finally, it is clear that we are now beginning to tailor our
therapy choices based on better understanding of both tumor
and host biology. It took decades for us to recognize that
interventions like tamoxifen and OS are most effective for
cancers that express HR. The advent of genomic and
proteomic assays that allow analysis of multiple variables of
the tumor simultaneously will surely enhance our ability to
select endocrine therapy for the individual patient more
precisely. Indeed tests like the Oncotype Dx assay are but the
first step in this process. Similarly, in the near future, we may
also need to tailor our treatment based on the biology of the
host. Currently, choice of endocrine therapy is made, in part,
on the patient’s menopausal status. It is likely that other
measures, such as pharmacogenetic assays, will increasingly
come into play. For example, early work suggests that
response to tamoxifen may be influenced by single nucleotide
polymorphisms in the CYP2D6 gene, a member of the
cytochrome p450 family that plays a role in converting
tamoxifen to its active metabolite, endoxifene. Seven to ten
percent of Caucasians have CYP2D6 variants, and patients
with homozygous CYP2D6 variants may have decreased
CYP2D6 activity and endoxifene levels in small studies of
breast cancer patients receiving tamoxifen [9]. Further study
to confirm these findings, investigate the role of other
CYP2D6 variants, and determine the clinical ramifications of
these variants is needed before CYP2D6 genotype
determination should become a routine test to determine
tamoxifen use [10]. It is highly likely such tumor- and host-
based assays will be an increasingly common part of
oncology in the 21st century.
It is sobering to compare the slow pace of development of
endocrine therapy in premenopausal women with HR-
responsive breast cancer with the development of anti-HER-2
based therapy. The former has taken over 100 years while the
first anti-HER-2 therapy went from identification of the target
gene/protein to proof of survival benefit of trastuzumab in
women with advanced breast cancer that over-expresses
HER-2 protein in less than 20 years. This comparison
reminds us of the importance of targeting therapy based on a
good understanding of cancer biology and the value of well-
designed and adequately powered clinical trials.
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